V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016959 | 160019836 | 1.82 | 68 | Curative (C) | 2020-12-16 | 2020-12-30 | null | 02 | Y | LENVATINIB | 100659204 |
| 160016971 | 160019837 | 1.76 | 90.8 | Curative (C) | 2019-12-08 | 2019-12-08 | IDELALISIB | 01 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 100977599 |
| 160016975 | 160019838 | 1.62 | 12 | Curative (C) | 2019-07-20 | 2019-08-24 | Cyclophosphamide + Topotecan | 02 | N | RMS 2005 TRIAL | 100761456 |
| 160016986 | 160019839 | 1.83 | 74 | Adjuvant (A) | 2019-01-15 | 2019-02-01 | DABRAFENIB + TRAMETINIB | 02 | N | CYCLOPHOSPHAMIDE + TOPOTECAN | 100200365 |
| 160016990 | 160019840 | 0 | 14 | null | 2021-12-30 | 2022-01-17 | Dacarbazine | null | null | ETOP 13-18 BEAT-MESO TRIAL | 101822042 |
| 160016993 | 160019841 | 1.7 | 17.8 | Palliative (P) | 2020-01-02 | 2020-01-09 | EW EuroEwing 2012 Arm B IE | 02 | N | NB LOW/INTERMED RISK GUIDELINES CADO | 100212183 |
| 160016996 | 160019842 | 0.6 | 86.2 | null | 2021-04-23 | 2021-09-26 | Sunitinib | 01 | null | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 100086284 |
| 160017000 | 160019843 | 1.81 | 11.6 | null | 2018-03-09 | 2018-03-27 | Melphalan IV High dose | 02 | null | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 101514865 |
| 160017011 | 160019844 | 1.63 | 25.7 | Palliative (P) | 2018-07-08 | 2018-11-21 | NB Low/Intermed risk guidelines CADO | 02 | N | EW EUROEWING 2012 ARM A VIDE | 100970885 |
| 160017014 | 160019845 | 1.53 | 23.5 | null | 2016-06-06 | 2016-06-09 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | null | RMS 2005 TRIAL | 101467040 |
| 160017030 | 160019846 | null | 120 | null | 2017-10-06 | 2017-11-18 | Carboplatin + Liposomal Doxorubicin | 02 | null | STS RHABDO RMS 2005 2ND TOPO CARBO | 101823003 |
| 160017045 | 160019847 | 1.79 | 11.3 | Curative (C) | 2019-09-05 | 2019-09-19 | PEMBROLIZUMAB | 02 | Y | CARBOPLATIN + VINORELBINE | 100263234 |
| 160017054 | 160019849 | 1.63 | 73.7 | Curative (C) | 2022-01-27 | 2022-02-13 | NB HRNBL-1 TVD | 02 | N | DACARBAZINE + GEMCITABINE | 101068411 |
| 160017067 | 160019850 | 0 | 31 | Palliative (P) | 2021-02-17 | 2021-02-24 | null | 02 | N | IVA | 100157495 |
| 160017076 | 160019851 | 1.62 | 73 | Palliative (P) | 2020-04-07 | 2020-04-08 | Doxorubicin + Ifosfamide | 02 | N | CYCLOPHOSPHAMIDE + VINCRISTINE | 101525979 |
| 160017106 | 160019852 | 1.06 | 48 | Curative (C) | 2021-10-12 | 2021-10-12 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | Y | RUCAPARIB | 100451101 |
| 160017119 | 160019853 | 1.78 | 49.3 | Curative (C) | 2020-04-01 | 2020-07-24 | FLUOROURACIL + IRINOTECAN | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 100674859 |
| 160017127 | 160019854 | 1.64 | 88 | Curative (C) | 2022-02-17 | 2022-03-01 | IMATINIB | 02 | N | TEMOZOLOMIDE | 101584547 |
| 160017128 | 160019855 | null | 77.3 | Palliative (P) | 2017-04-02 | 2017-04-22 | GEMCITABINE | 02 | N | EW EUROEWING 2012 ARM B IE | 100315424 |
| 160017143 | 160019857 | 1.8 | 14.5 | Curative (C) | 2021-12-26 | 2022-01-02 | DACTINOMYCIN + CYCLO + VINCRISTINE | 02 | Y | GEMCITABINE | 101237274 |
| 160017158 | 160019858 | 1.77 | 64.3 | Neo-adjuvant (N) | 2019-04-06 | 2019-04-06 | Cyclophosphamide + Topotecan | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101600360 |
| 160017159 | 160019859 | 1.84 | 71.5 | Curative (C) | 2020-12-14 | 2020-12-14 | Ipilimumab | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 101794810 |
| 160017176 | 160019861 | 1.71 | 78 | null | 2020-07-12 | 2020-09-08 | null | 02 | null | EW REL REECUR IRINOTECAN/TEMOZOLOMIDE | 100445707 |
| 160017196 | 160019862 | 0 | 78.7 | null | 2018-11-28 | 2019-03-08 | NB HRNBL-1 COJEC Ind COURSE C | 99 | null | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 100729238 |
| 160017216 | 160019863 | 1.53 | 56.7 | Palliative (P) | 2019-04-11 | 2019-04-19 | EW EuroEwing 2012 Arm A VIDE | 02 | N | NIRAPARIB | 101196585 |
| 160017220 | 160019864 | 1.67 | 60.9 | Curative (C) | 2016-12-26 | 2017-04-10 | LORLATINIB | 02 | N | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 101402976 |
| 160017222 | 160019865 | 1.7 | 92.9 | null | 2019-12-03 | 2019-12-09 | EW EuroEwing 2012 Arm B IE | 02 | null | VINCRISTINE | 100311295 |
| 160017251 | 160019866 | 1.67 | 63.1 | null | 2018-04-07 | 2018-05-12 | Doxorubicin + Ifosfamide | 02 | null | OLAPARIB | 101434073 |
| 160017260 | 160019867 | 1.63 | 67 | null | null | 2020-04-03 | Trial Unspecified | 02 | null | VINCRISTINE | 100969350 |
| 160017277 | 160019868 | 1.78 | 74.6 | null | 2021-08-24 | 2022-03-01 | Cisplatin + Doxorubicin | 01 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 100030899 |
| 160017287 | 160019869 | null | 0 | null | 2017-02-09 | 2017-09-15 | CONFIRM TRIAL | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101651506 |
| 160017297 | 160019870 | null | null | Curative (C) | 2020-01-22 | 2020-01-31 | FLUOROURACIL + IRINOTECAN | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 101018565 |
| 160017328 | 160019871 | 1.65 | 25.5 | null | 2020-12-29 | 2020-12-29 | null | 01 | null | NB LOW/INTERMED RISK GUIDELINES CADO | 101659424 |
| 160017335 | 160019872 | 1.73 | 83.6 | Neo-adjuvant (N) | 2019-06-12 | 2019-06-18 | IRINOTECAN + VINCRISTINE | 01 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100789822 |
| 160017358 | 160019873 | 1.84 | 71.4 | Curative (C) | 2017-08-07 | 2017-08-07 | NB HRNBL-1 BUMEL MAT | 02 | N | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 100480278 |
| 160017375 | 160019874 | 1.66 | 64.4 | null | 2020-02-26 | 2020-03-04 | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 02 | null | PEMBROLIZUMAB | 101613656 |
| 160017378 | 160019875 | 1.73 | 74.6 | null | 2018-11-01 | 2018-12-16 | Carboplatin + Vinorelbine IV | 02 | null | IFOSFAMIDE | 100810764 |
| 160017385 | 160019876 | 1.63 | 81.14 | Palliative (P) | 2018-08-07 | 2018-08-17 | Ifosfamide | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100674697 |
| 160017388 | 160019877 | 1.68 | 0 | Palliative (P) | 2021-04-10 | 2021-04-12 | IPM | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 101109548 |
| 160017396 | 160019878 | 1.6 | 18 | null | 2021-03-10 | 2021-03-14 | VAC | 02 | null | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 101280426 |
| 160017419 | 160019879 | null | 48.9 | null | 2016-07-01 | 2016-08-24 | Doxorubicin + Ifosfamide | 02 | null | GEMCITABINE | 100343892 |
| 160017435 | 160019880 | 1.67 | 46.4 | Palliative (P) | 2019-10-29 | 2019-10-29 | Cyclophosphamide High Dose | 01 | N | DOXORUBICIN + IFOSFAMIDE | 100270980 |
| 160017454 | 160019881 | 1.79 | 56.1 | null | 2017-10-23 | 2017-11-01 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | null | TRIAL | 100695137 |
| 160017476 | 160019882 | 1.63 | 50.1 | Palliative (P) | 2018-03-15 | 2018-04-03 | Dinutuximab Beta | 01 | N | NB HRNBL-1 BUMEL MAT | 101680592 |
| 160017490 | 160019883 | 1.62 | 60.3 | null | null | 2019-04-12 | NEMO TRIAL | 02 | null | ETOPOSIDE + IFOSFAMIDE | 100770715 |
| 160017495 | 160019884 | 1.57 | 12 | Curative (C) | 2019-06-22 | 2019-06-22 | GEMCITABINE | 02 | null | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 100568199 |
| 160017548 | 160019885 | 0 | 72.5 | null | 2016-08-18 | 2016-11-16 | ETOP 13-18 BEAT-meso Trial | 02 | null | TRIAL | 100915208 |
| 160017554 | 160019886 | 1.71 | 72 | null | 2020-10-28 | 2020-10-30 | VINCRISTINE | 02 | null | STS RHABDO RMS 2005 VIN CYCLO | 101244428 |
| 160017556 | 160019887 | 1.78 | 56.6 | Curative (C) | 2021-08-02 | 2022-02-05 | null | 02 | N | ETOPOSIDE + IFOSFAMIDE | 101502820 |
| 160017573 | 160019888 | 1.67 | 21.8 | Palliative (P) | 2016-07-10 | 2016-07-19 | Doxorubicin + Ifosfamide | 01 | N | DOXORUBICIN + IFOSFAMIDE | 100093601 |